CompoAtlas

Vari-Vein

En venta en el mercado estadounidense (según DSLD)

Crystal Star, complemento alimenticio del mercado estadounidense

Vari-Vein (Crystal Star), complemento alimenticio au code-barres 747889041907, se describe mediante su etiqueta del mercado estadounidense. Si se vendiera en Francia, le afectarían 2 puntos de la normativa francesa o europea, detallados a continuación. La fórmula vendida en Europa con el mismo nombre puede ser diferente.

Etiqueta oficial. Dietary Supplement Label Database (DSLD), Institutos Nacionales de la Salud de Estados Unidos (NIH): etiquetas a la venta o retiradas del mercado, consultado el 27 de octubre de 2026.

Fuente: NIH, Office of Dietary Supplements, Dietary Supplement Label Database (CC0); etiquetas del mercado estadounidense.

Si este producto se vendiera en Francia

Solo se calcula una dosis diaria si la etiqueta indica el número máximo de tomas y una unidad de masa (o unidades internacionales para la vitamina D). Las cantidades proceden de la etiqueta, no de un análisis. En Estados Unidos, la etiqueta presenta este producto como «dietary supplement»; en Francia, un producto de este tipo puede pertenecer a otra categoría (por ejemplo, un polvo para deportistas) y las dosis máximas de los complementos alimenticios no serían aplicables.

Composición de la etiqueta

Marca
Crystal Star
Código de barras
747889041907
Forma
Cápsula
Una toma
2 cápsulas
Tomas
como máximo 1 toma al día
Otros ingredientes (en inglés, tal como están escritos)
Ingrediente (tal como aparece, en inglés)CategoríaPor toma
Proprietary Herbal BlendMezcla1,3 Gram(s)
HawthornPlantano indicada
Gotu Kola (Centella asiatica)Plantano indicada
Green Tea (Camellia sinensis)Plantano indicada
RosemaryPlantano indicada
White Tea extract (Camellia sinensis)Plantano indicada
Butcher's Broom (Ruscus aculeatus)Plantano indicada
Grape seed extractPlantano indicada
BilberryPlantano indicada
Horse Chestnut extract (Aesculus hippocastanum)Plantano indicada
Poria Cocos (Wolfiporia cocos)Plantano indicada
Goldenseal (Hydrastis canadensis)Plantano indicada
Amla (Phyllanthus emblica)Plantano indicada
Witch Hazel (Hamamelis virginiana)Plantano indicada
LyciumPlantano indicada
Ginkgo biloba extractPlantano indicada
Eucalyptus (Eucalyptus globulus)Plantano indicada
Prickly AshPlantano indicada
GingerPlantano indicada
Cayenne (Capsicum annuum)Plantano indicada
KelpPlantano indicada
Sea BuckthornPlantano indicada
Irish Moss (Chondrus crispus)Plantano indicada

Etiqueta mostrada: Etiqueta oficial. Se priorizan las etiquetas a la venta y, después, la más reciente para un mismo estado.

Otras versiones de esta etiqueta

Las diferencias siguientes describen cada versión respecto a la etiqueta mostrada en esta ficha. Se refieren a las filas de ingredientes activos y a las cantidades por toma tal como están escritas. No se estiman las cantidades ausentes ni se convierten las unidades diferentes. Las fechas corresponden a la entrada en el DSLD, no necesariamente a un cambio de fórmula.

Esta información recoge la etiqueta estadounidense registrada por los Institutos Nacionales de la Salud de Estados Unidos (NIH). No indica si el producto es eficaz ni sustituye el consejo de un médico o farmacéutico, especialmente durante el embarazo o un tratamiento.

Advertencias oficiales (Health Canada)

Health Canada publica advertencias sobre estos ingredientes:

  • Horse Chestnut extract
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    Horse Chestnut - Aesculus Hippocastanum

    Vía de administración: Oral (Bradley 2006; ESCOP 2003)

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Mills and Bone 2005).

    Fuentes citadas por Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Reacciones adversas conocidas

    When using this product you may experience headache, dizziness, gastric irritation, or itchiness (Bradley 2006; Mills and Bone 2005; ESCOP 2003).

    Fuentes citadas por Health Canada (3)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (UK): British Herbal Medicine Association; 2006.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Monografía de Health Canada del 27 de febrero de 2026

  • Goldenseal
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    GOLDENSEAL - HYDRASTIS CANADENSIS - Buccal

    Precauciones y advertencias

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Ask a health care practitioner/health care provider/health care professional/ doctor/physician before use if you have a kidney or blood pressure disorder (Brinker 2010; Hoffmann 2003).

    Fuentes citadas por Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.

    Contraindicaciones

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes and al. 2007; Mills and Bone 2005; Boon and Smith 2004; Hoffmann 2003; Bradley 1992).

    Fuentes citadas por Health Canada (7)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press; 2007.
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Monografía de Health Canada del 28 de marzo de 2025

    GOLDENSEAL - HYDRASTIS CANADENSIS - Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional before use if you have a kidney or blood pressure disorder (Brinker 2010; Hoffmann 2003).

    Fuentes citadas por Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Hoffmann D. 2003. Medical Herbalism. Rochester (VT): Healing Arts Press.

    Contraindicaciones

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes and al. 2007; Mills and Bone 2005; Boon and Smith 2004; Hoffmann 2003; Bradley 1992).

    Fuentes citadas por Health Canada (7)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • Boon H, Smith MJ. 2004. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc.
    • Bradley PR, editor. 1992. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Hoffmann D. 2003. Medical Herbalism. Rochester (VT): Healing Arts Press.
    • Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.

    Monografía de Health Canada del 29 de noviembre de 2024

  • Amla
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    Amla - Phyllanthus Emblica

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).

    Fuentes citadas por Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Se aplica a los productos: providing more than 3 grams of amla, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).

    Fuentes citadas por Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Condición de aplicación: Amlapitta, Digestive tonic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condición de aplicación: Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).

    Fuentes citadas por Health Canada (3)
    • CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.

    Contraindicaciones

    Condición de aplicación: Laxative.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Fuentes citadas por Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Reacciones adversas conocidas

    Condición de aplicación: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.

    When using this product you may experience a laxative effect.

    Monografía de Health Canada del 28 de marzo de 2025

  • Witch Hazel
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    WITCH HAZEL - HAMAMELIS VIRGINIANA Buccal and Oromucosal

    Vía de administración: Buccal Oromucosal

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 27 de febrero de 2026

    WITCH HAZEL - HAMAMELIS VIRGINIANA Ophthalmic

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or persist (for) more than 2 days (EMA 2009).

    Fuentes citadas por Health Canada (1)
    • EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience eye pain, changes in vision, continued redness, or irritation of the eye (EMA 2009).

    Fuentes citadas por Health Canada (1)
    • EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf

    Monografía de Health Canada del 27 de febrero de 2026

    WITCH HAZEL -HAMAMELIS VIRGINIANA Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    Fuentes citadas por Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Reacciones adversas conocidas

    When using this product you may experience gastrointestinal discomfort/disturbances (Gardner and McGuffin 2013; ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).

    Fuentes citadas por Health Canada (4)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.

    Monografía de Health Canada del 27 de febrero de 2026

    WITCH HAZEL - HAMAMELIS VIRGINIANA Topical

    Precauciones y advertencias

    Condición de aplicación: All products.

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Se aplica a los productos: for use on minor wounds/burns/bruises/irritations/inflammations or on hemorrhoids.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen, last (for) more than 7 days.

    Se aplica a los productos: for use on varicose veins.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindicaciones

    Se aplica a los productos: for use on minor wounds/burns/bruises/irritations/inflammations.

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Reacciones adversas conocidas

    Condición de aplicación: All products.

    Stop use if a skin rash occurs (ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).

    Fuentes citadas por Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Se aplica a los productos: for use on hemorrhoids.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience bleeding.

    Monografía de Health Canada del 27 de febrero de 2026

  • Cayenne
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    CAYENNE - CAPSICUM ANNUUM Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    Fuentes citadas por Health Canada (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    Fuentes citadas por Health Canada (2)
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    Fuentes citadas por Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Condición de aplicación: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 27 de marzo de 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Precauciones y advertencias

    Condición de aplicación: All products.

    For external use only (US FDA 2023).

    Fuentes citadas por Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    Fuentes citadas por Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    Fuentes citadas por Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    Fuentes citadas por Health Canada (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Reacciones adversas conocidas

    Condición de aplicación: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    Fuentes citadas por Health Canada (5)
    • APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
    • Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
    • McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Ensayo aleatorizado
    • Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Revisión sistemática

    Monografía de Health Canada del 27 de marzo de 2026

Se refieren al ingrediente, no a este producto ni a su dosis. No sustituyen el consejo médico.

Lista declarada el (registro: Dietary Supplement Label Database (DSLD), Institutos Nacionales de la Salud de Estados Unidos (NIH): etiquetas a la venta o retiradas del mercado).

Fotografiar el envase

Marca : Crystal Star

¿Alguna información inexacta o más reciente sobre este producto, sea usted lector o marca? Escriba a contact@compoatlas.com: cada corrección se publica en el registro de correcciones.

Lista registrada en 2021. Fotografíe el envase para comprobar si ha cambiado.

Intro para analizar, Mayús+Intro para una nueva línea